Status:
COMPLETED
Pearl Index Study With Low Dose Combined Oral Contraceptive
Lead Sponsor:
Bayer
Conditions:
Contraception
Eligibility:
FEMALE
18-40 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate the contraceptive efficacy, bleeding pattern, and safety of SH D00342A. Subjects participating in the study will be treated with an oral contraceptive pill ...
Detailed Description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Eligibility Criteria
Inclusion
- Healthy women requiring contraception
Exclusion
- Pregnant or lactating women, history or suspicion of hormone dependent tumor or any other conditions which forbid the participation.
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2005
Estimated Enrollment :
840 Patients enrolled
Trial Details
Trial ID
NCT00220324
Start Date
February 1 2004
End Date
November 1 2005
Last Update
April 3 2015
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Hanover, Lower Saxony, Germany, 30159
2
Dresden, Saxony, Germany, 01067
3
Dresden, Saxony, Germany, 01099
4
Dresden, Saxony, Germany, 01108